What stops one drug getting into another

The problem has a plain name

A pharmacy or a facility that prepares more than one product has a hazard that a single-product operation does not. Material from one preparation can end up in another.

The agency defines it without ceremony. Drug cross-contamination is the contamination of one drug with one or more different drugs.

That is a different problem from the one most quality writing is about. Sterility is about organisms getting into a product from its surroundings, and a separate article on this site covers the rooms and the air where that battle is fought.

This is about a second medicine getting into the first. The controls are different, and so is the reasoning behind them.

The general rule is separation by design

For almost everything, the manufacturing rules answer the problem with layout and procedure rather than with walls.

A building has to have adequate space for the orderly placement of equipment and materials, to prevent mixups between different components, containers, closures, labeling, in-process materials or drug products, and to prevent contamination.

The flow of all of those things through the building has to be designed to prevent contamination. Design is the operative word. The route material takes is itself a control.

Then the rule gets specific about where separation is required. Operations have to be performed within specifically defined areas of adequate size, and there have to be separate or defined areas, or other control systems, for a list of ten activities.

The list runs from receipt and quarantine of incoming material, through storage of released material and in-process material, through manufacturing and packaging, to quarantine before release, storage after release, and laboratory operations.

Read it as a description of a facility as a set of separated states rather than as a set of rooms. Defined areas is one of the permitted answers, and so is such other control systems as are necessary.

One drug gets a building

Then the part changes register entirely for a single substance.

Operations relating to the manufacture, processing and packing of penicillin have to be performed in facilities separate from those used for other drug products for human use.

A second section covers what moves between rooms even when people do not. Air-handling systems for penicillin have to be completely separate from those for other drug products for human use.

Both of those are requirements rather than recommendations, and neither has a comparable twin anywhere else in the part.

FDA has softened one edge of the first. The agency has clarified that separate buildings may not be necessary, provided the section of the facility dedicated to penicillin is isolated. It glosses isolated as completely and comprehensively separated from the areas where non-penicillin products are made.

That clarification comes from the preamble to the original rule, and it is a statement about what separate means. It is not a relaxation of the requirement.

And a test with a marketing prohibition attached

The third penicillin rule sits in the laboratory controls subpart, and it is the strongest of the three.

If a reasonable possibility exists that a non-penicillin drug product has been exposed to cross-contamination with penicillin, that product has to be tested for the presence of penicillin.

The trigger is a reasonable possibility of exposure, not a finding. The obligation begins with the circumstances.

Then comes the sentence with no discretion in it. Such drug product shall not be marketed if detectable levels are found.

The test itself is not left to the reader either. It has to follow procedures in a document the regulation incorporates by reference, named in the section and held in the federal archives. The rule specifies the method as well as the outcome.

A prohibition on marketing is rare in a manufacturing regulation. Most of the part describes what has to be done. This one describes what may not be sold.

Why that drug, and not the others

The reason is not that penicillin is more toxic than other medicines. It is that trace amounts can do harm to people who are sensitized to it.

FDA states the mechanism in a guidance on the wider class. Penicillin can be a sensitizing agent that triggers a hypersensitive exaggerated allergic immune response in some people.

The same document lists three features that make the hazard hard to manage by measurement rather than by separation.

It is difficult to define the minimal dose below which allergic responses are unlikely to occur in humans. There is a lack of suitable animal or receptor testing models that are predictive of human sensitivity. And the threshold dose at which an allergenic response could occur is extremely low and difficult to detect with current analytical methods.

Put those together and the case for physical separation writes itself. If you cannot say how little is too little, and you cannot reliably find the amount that matters, then the control has to be that it never gets there.

That is also why an allergy of this kind is a different subject from an ingredient warning. A preservative added on purpose is disclosed on the label, and a separate article on this site covers what else is in a vial. A contaminant is not on anybody's label.

The agency extended the reasoning, without extending the rule

Penicillin belongs to a wider family of antibiotics that share a chemical feature, and FDA published a guidance about the rest of that family.

The five classes it names are penicillins, cephalosporins, penems, carbacephems and monobactams. Non-penicillin members of the family can sensitize people too, and can trigger the same kinds of reaction.

The recommendation is symmetrical with the regulation. The area where any class of sensitizing beta-lactam is made should be separated from areas where any other products are made, and should have an independent air handling system.

It goes one step further than the regulation in one respect. The separation is recommended between the classes as well, so one sensitizing family should be kept out of another. Within a single class, campaigning and cleaning can be enough.

The important qualification is one the guidance makes about itself. Guidance documents do not establish legally enforceable responsibilities, and the word should in an FDA guidance means suggested or recommended, not required.

So the shape of this subject is a hard rule for one drug and a documented recommendation for its relatives. Treating the second as though it were the first would be a claim the agency does not make.

What the part names, and what it does not

It is worth being precise about how narrow the named list is.

Across all sixty sections of the manufacturing part, penicillin is the only drug singled out for contamination control. It appears in three of them: the buildings section, the ventilation section and the laboratory controls section.

One material is prohibited outright rather than separated, and it is not a drug at all. Asbestos-containing filters may not be used, in the section on filters that an article on this site covers.

No peptide is named anywhere in the part, and neither is any other class of compound. Everything except penicillin is handled by the general machinery: designed flow, defined areas, written procedures, a quarantine system for rejected material, and separation of packaging and labeling operations from operations on other products.

The last of those has its own section and its own article here, because a mislabeled container is the version of this problem that reaches a buyer most often.

Who these rules bind, and what a reader can ask

The regulation states its own reach. It contains the minimum current good manufacturing practice for preparation of drug products for administration to humans or animals.

Whether a given compounder is held to it depends on which part of the compounding statute that facility operates under, because the two categories are exempted from different lists of requirements. That comparison is the subject of the article on what a compounding exemption actually exempts.

FDA speaks to the wider audience directly in the beta-lactam guidance. It says the information is intended for manufacturers of finished pharmaceuticals and active pharmaceutical ingredients, including repackagers, and that other establishments that handle drugs, such as pharmacy compounders, may find it useful.

Two questions follow for a reader looking at a facility that makes many different preparations. Does anything published describe how products are kept apart, as distinct from how the room is kept clean. And does a stated separation describe defined areas and written procedures, which is what the general rule asks for, or a dedicated facility and dedicated air, which the rule asks for once.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Title 21 Code of Federal Regulations Section 211.176, Penicillin contamination, requiring a non-penicillin drug product to be tested where a reasonable possibility of cross-contamination exists, prohibiting its marketing if detectable levels are found, and incorporating by reference the procedures for detecting and measuring penicillin contamination — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
2. Title 21 Code of Federal Regulations Section 211.42, Design and construction features, including the requirement for adequate space to prevent mixups, a material flow designed to prevent contamination, separate or defined areas for ten named activities, and separate facilities for operations relating to penicillin — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
3. Title 21 Code of Federal Regulations Section 211.46, Ventilation, air filtration, air heating and cooling, whose paragraph (d) requires air-handling systems for penicillin to be completely separate from those for other drug products for human use — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
4. Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination — Guidance for Industry, defining drug cross-contamination, naming the five classes of sensitizing beta-lactams, recommending separated facilities and independent air handling, and stating that guidance does not establish legally enforceable responsibilities — U.S. Food and Drug Administration, Center for Drug Evaluation and Research, April 2013
5. Title 21 Code of Federal Regulations Section 211.1, Scope, stating that the part contains the minimum current good manufacturing practice for preparation of drug products for administration to humans or animals — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026